Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, targeting SCAI Stage C ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical ...

The latest evidence on the treatment of urgent heart problems ... devices to support adults with rapidly deteriorating or severe cardiogenic shock was feasible but did not improve clinical ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Three secondary analyses clarified how the Impella pump works in STEMI with cardiogenic shock, and how things can go wrong.

The istaroxime patent is entitled, “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF PRE-CARDIOGEN1C SHOCK AND CARDIOGENIC SHOCK”, is No. PCT/US2023/018998 and was assigned ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

The researchers conducted a retrospective single-center cohort study by analyzing past data taken from 114 patients with cardiogenic shock. These patients received treatment with VA-ECMO or the ...

ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.

Windtree is collaborating with Lee’s on the Phase 3 program and has final signing authority on the protocol. Acute heart failure is the #1 cause of hospitalization in patients >65 years of age in many ...

Two DLT events of autoimmune hepatitis and cardiogenic shock were reported. Each event occurred in 2 separate participants who received FCA lymphodepletion and DL2 of ALLO-316. Three Grade 5 treatment ...